Share Name Share Symbol Market Type Share ISIN Share Description
Port Erin LSE:PEBI London Ordinary Share IM00B6QH1J21 ORD 0.0001P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 5.25p 5.00p 5.50p 5.25p 5.25p 5.25p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.5 -2.3 - 1.58

Port Erin Share Discussion Threads

Showing 201 to 224 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
16/6/2017
12:42
i wonder if jim will use the cash from the magna sale here to invest in DBC- it needs a rescue
kristini2
17/5/2017
21:46
A Red Letter day?; someone else bought PEBI !
tightfist
25/4/2017
10:32
I had a nibble at 6.875p, immediately dropped the Bid to 6p.
tightfist
25/4/2017
10:24
Hi Rivaldo,I trust JM with our cash and I doubt that it will be frittered away, unlike some other companies...... A distribution would be nice, a tender offer at NAV for 10% of our holdings would reward our patience and only put a 30% dent in that cash pile.Cheers, tightfist
tightfist
25/4/2017
10:02
This is good news imo tightfist. Almost £1m of cash will bring in the liquidity necessary to get the various newer ventures off the blocks and running. The only worry is of course that it'll be frittered away. However, hopefully DBC is back on course now after JM's intervention with new appointments etc. Perhaps once the proceeds have actually been received there may be news of shareholder distributions etc.
rivaldo
25/4/2017
09:26
All quiet after this morning's surprise RNS. Cash will constitute ~70% of NAV leaving the remaining investments value at ~30% of NAV.Now there are opportunities to significantly play a part within other JM ventures, getting in on the ground floor? Will this cash play a part in the pre-IPO surrounding DBC, LIFE and RPG?No mention of cash redemptions to shareholders to close/offset the discount. I am not sure if I should be disappointed by that?Cheers, tightfist
tightfist
09/4/2017
21:00
Many thanks Rivaldo - as Ochs says, straight from the horse's mouth, and seems like some sincerity regarding DBC. I was not aware that RPG were a substantial holder in DBC, but I should not be surprised. I guess PEBI's direct holding is a lot less than their indirect holding. Cheers, tightfist
tightfist
09/4/2017
17:40
Interesting update rivaldo and right from the horses mouth! So he was still positive about DBC?
ochs
06/4/2017
08:22
News this morning of DBC - there is life! Life Science will de-list from AIM, but intend to carry out the DBS takeover and re-list on AIM, with a new financing etc. Let's hope DBC survives and continues: Http://www.investegate.co.uk/life-science-dev-ltd--life-/rns/update-on-potential-acquisition/201704060700117298B/ I was fortunate enough to see Jim Mellon present last night to a small gathering. Amongst other topics he ran through some of his portfolio of companies. He didn't include PEBI specifically. However... - I asked him afterwards about the discount to NAV etc, having noted I knew it was difficult for him to say anything not in the public arena. He and his colleague however were decidedly upbeat.... - re Plethora/Fortacin, Recordati have plans to produce 50,000 cans a day, which would produce £1m royalties per day to Regent Pacific - re DBC, there had been disappointing management execution, but there's new management now, and the product works - JM did specifically talk about SalvaRx in his presentation and was VERY bullish.
rivaldo
29/3/2017
12:14
Hi,Thanks for the Northland info;,I also need to keep an eye on SalvaRx!This is a real game of patience; I suppose that is OK as long as I believe in the NAV increasing and the Discount decreasing before I reach the door of the old people's home.....Cheers, tightfist
tightfist
29/3/2017
10:58
Yep, it seems like the wait continues for concrete action, whether by PEBI to reduce the discount or one of the portfolio investees to surge. Or for a press mention of the 40% discount to NAV :o)) FYI Northland have updated as follows today: "Northland Capital partners view: PEBI reported a strong gain in its Net Asset Value, up 20% YoY. Nevertheless, there is significant upside to the Company’s shares, as the Group’s market valuation still remains at a c. 50% discount to the underlying asset base. The Company's investments continue to show significant potential. Of note, Northland’s price target on one of PEBI’s portfolio holdings, namely SalvaRx, is 149p, while SalvaRx’s current share price is 30p. We also see significant upside to several other PEBI holdings."
rivaldo
29/3/2017
09:39
Hi Rivaldo,Yes, it's good to see recognition of the discount issue, though action is more elusive.....Also interesting to see a little more info on the unquoted side with Luminor and SavaRx, those two plus DBC/Pulse-flow is where the cash from SUMM and Magna sales has been reinvested.By now I was expecting to see more on DBC reversing into LIFE; the clock is ticking!Cheers, tightfist
tightfist
29/3/2017
08:35
Final results out today - NAV of 11.13p per share. The share price discount is described as "significant and disappointing", with "a number of options" being considered. It's decision time for DBC with PEBI's loan being due for repayment by 31st March.
rivaldo
27/3/2017
21:46
It seems to me that PEBI has entered a complete backwater within the Mellon camp, it is getting minimal attention? I was hoping that Mellon would want to close it with a respectable result, to keep his record clean? The talk of closing the discount has come to nothing, after Tranche 1 in Autumn 2015.
tightfist
26/3/2017
09:53
Nobody on the PEBI stand at Master Investor yesterday. Shabby.
snape
09/3/2017
19:11
Hi Rivaldo,I reckon the NAV stands at about 11.3p. IIRC the DBC loan has to be settled by end March? I wonder how the IPO us shaping-up.Cheers, tightfist
tightfist
01/3/2017
12:37
Both Magna and Regent Pacific continue to do well, and SUMM is also climbing. The next NAV announcement should be interesting.
rivaldo
15/2/2017
11:56
The NAV looks to be up at around 11.4p and the discount back up to around 47%. Some things never change! tightfist
tightfist
12/1/2017
07:37
This explains the interest ! NAV of 11.13 pence Pacific group doing well. RNS Number : 9529T Port Erin Biopharma Investments Ltd 12 January 2017 Port Erin Biopharma Investments Limited (the "Company") Net Asset Value calculation to 31 December 2016 Jim Mellon, Chairman, commented: - "The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2016 was 11.13 pence per share, including un-invested cash of GBP66,642. The portfolio is valued under IFRS at bid price. Net Assets stand at GBP2.62 million including investments of GBP2.55 million. This quarter's NAV represents an increase of 11.7% from the previous valuation of 9.96 pence per share, which included un-invested cash of GBP12,921. No management fee is due to Shellbay Investments Limited. The increase in reported NAV to 31 December 2016 is mainly due to an upturn in the value of the holding in Regent Pacific Group. The Company's three principal investments continue to show significant growth potential during 2017 and beyond". Unaudited to 31 December 2016 GBP Fixed Assets Investments 2,548,237 Current Assets Sundry Debtors 8,592 Uninvested cash 66,642 Current Liabilities Creditors: amounts due (41,962) --------------------------------- 2,581,509 Capital and Reserves Share Capital 23 Share Premium 1,890,142 Reserves 691,344 --------------------------------- 2,581,509 Shares in Issue 23,195,558 Net Asset Value per share 11.13 pence Portfolio Details Investments as at 31 Value % of Total Portfolio December 2016 ------------------------- ------------- -------------------- Magna Biopharma Income Fund GBP953,318 37.41% Regent Pacific Group GBP740,148 29.05% Summit Corporation GBP170,706 6.70% Investment loans GBP200,000 7.85% Other quoted holdings GBP136,845 5.37% Other unquoted holdings GBP347,220 13.62% Total GBP2,548,237 100.00% ------------------------- ------------- -------------------- For further information, please contact: Port Erin Biopharma Northland Capital Partners Peterhouse Capital Investments Limited Limited Limited The Company Nomad and Broker Broker Denham Eke Matthew Johnson / David Lucy Williams (+44) (0) 1624 639396 Hignell (+44) (0) 207 (+44) (0) 203 861 6625 469 0936 This information is provided by RNS
glyn10
11/1/2017
17:50
I am guessing the 489,343 shares was a buy at 8p? Mega volume, PI or Insti?
glyn10
04/1/2017
14:32
Why are the sellers not using the auction book process
hindsight
29/12/2016
13:18
Re pebi results out other day, bad is no mention of discount control this time and the 200k professional fees a big issue, costs jm 30%, 65k of that good is luminor and diabetic shoe company if hype true
hindsight
29/12/2016
12:51
not a good sign that JM may be using this vehicle to make loans to other companies he has an interest in ie recent loan from pebi to DBC i'm invested in DBC which is reversing in to a listed company currently in suspension
kristini2
16/12/2016
15:44
Would anyone like to do a spreadsheet swap, ie see if they tally and if not why not ?
hindsight
Chat Pages: 9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170921 08:53:17